Overview

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers

Status:
Completed

Trial end date:
2023-05-31

Target enrollment:

Participant gender:

Summary

This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 alone, in combination with sitagliptin, or in combination with K-833.

Phase:

Phase 1

Details

Lead Sponsor:

Kallyope Inc.

Treatments:

Sitagliptin Phosphate